bluebird bio, Inc.

bluebird bio reported third-quarter total revenue of $10.6 million, versus $16.1 million in Q2. Management said revenue fell sequentially because of manufacturing-timeline variation, but expects net revenue of at least $25 million in Q4 as more patients are infused. The company recognized its first LYFGENIA revenue in the quarter. Gross-to-net discounts were expected to remain in the 20% to 25% range in 2024, and R&D expense was down $36.1 million year over year while SG&A was generally consistent with the prior-year period. Cash and cash equivalents were $118.7 million at Sept. 30, 2024, including $48 million of restricted cash. Looking ahead, management reiterated a target of quarterly cash-flow breakeven in the second half of 2025, assuming about 40 drug product deliveries per quarter and additional cash resources.

Andrew Obenshain framed the quarter as evidence that the company’s commercial platform is starting to work, pointing to a more than doubling of patient starts since the prior earnings call and broad access across a growing QTC network. He emphasized that bluebird is seeing demand across its therapies and said the company has laid out a roadmap to financial stability and cash-flow breakeven in the second half of next year, contingent on securing more capital. His tone was confident but cautious, with repeated references to the need for additional financing.

James Sterling focused on revenue timing, costs, liquidity, and the reverse-split vote. He said Q3 revenue was $10.6 million, that the company expects at least $25 million of net revenue in Q4, and that gross-to-net discounts should stay in the 20% to 25% range in 2024. On costs, he noted SG&A was generally stable year over year while R&D was down $36.1 million, and he said recent cost-optimization actions should reduce cash operating expenses by 20% when fully realized in Q3 2025. Cash was $118.7 million at Sept. 30, inclusive of $48 million restricted cash, and he said existing cash should fund operations into Q1 2025. He also said the company is working with Hercules and other levers such as contract renegotiations to extend runway and support financing flexibility.

Analysts pressed on whether revenue weakness reflected drop-off after manufacturing or true patient attrition; management said pull-through after cell delivery remains 100%, and that most patients who come off schedule later return, with 14 patients coming off schedule this year for various reasons including hurricanes. Questions also focused on how far out 2025 scheduling is, and management said the vast majority of the 30 scheduled 2025 patients are in Q1, with some in Q2. On liquidity, management said it is collaborating with Hercules and pursuing cost reductions and contract renegotiations, while the proposed reverse stock split is intended to help regain NASDAQ compliance and preserve financing flexibility.